Please assess the completion status of the following clinical trial:

Trial Title: COBRA SHIELD OCT Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient \>= 18 years old.~* Eligible for percutaneous coronary intervention (PCI).~* Patient provides written informed consent.~* Patient is willing to comply with follow-up evaluation.~* Acceptable candidate for coronary artery bypass graft (CABG) surgery.~* Stable angina pectoris or a positive functional ischemia study.~* Male or non-pregnant female patient~* Patient indicated for elective stenting of up to 2 stenotic lesions in two separate native coronary arteries.~* Reference vessel \>=2.5 mm and\<= 4.0 mm in diameter by visual estimate.~* Target lesion \<=20 mm in length by visual estimate.~* Protected left main lesion with \>50% stenosis.~* Target lesion stenosis \>= 70% and \< 100% by visual estimate OR Target lesion stenosis \<70% who meet physiological criteria for revascularization (i.e. positive Fractional Flow Reserve).~Exclusion Criteria:~* Currently enrolled in another investigational device or drug trial.~* Previously enrolled in another stent trial within the prior 2 years.~* ANY planned elective surgery or percutaneous intervention within the subsequent 3 months.~* A previous coronary interventional procedure of any kind within 30 days prior to the procedure.~* The patient requires staged procedure of either the target or any non-target vessel before OCT procedure at 3 months post-procedure.~* The target lesion requires treatment with a device other than percutaneous transluminal coronary angioplasty (PTCA) prior to stent placement.~* Previous drug eluting stent (DES) or bare metal stent (BMS) deployment anywhere in the target vessel.~* Co-morbid condition(s) that could limit the patient's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial.~* Concurrent medical condition with a life expectancy of less than 12 months.~* Documented left ventricular ejection fraction (LVEF) \< 50% at the most recent evaluation.~* Patients with diagnosis of myocardial infarction (MI) within 72 hours (i.e. CK-MB must be returned to normal prior to enrollment) or suspected acute MI at time of enrollment.~* Previous intervention in the target vessel.~* History of cerebrovascular accident or transient ischemic attack in the last 6 months.~* Leukopenia (leukocytes \< 3.5 x10\^9 / liter).~* Neutropenia (Absolute Neutrophil Count \< 1000/mm3) \<= 3 days prior to enrollment.~* Thrombocytopenia (platelets \< 100,000/mm3) pre-procedure.~* Active peptic ulcer or active GI bleeding.~* History of bleeding diathesis or coagulopathy or inability to accept blood transfusions.~* Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, L-605 Cobalt chromium alloy or sensitivity to contrast media, which cannot be adequately pre-medicated.~* Serum creatinine level \> 2.0 mg/dl within 7 days prior to index procedure.~* Patients not responsive to Plavix/ aspirin and or unable to tolerate Plavix/ aspirin for 6 month post procedure.~* Patient on or may require anticoagulation therapy within 3 months of index procedure.~* Flow limiting dissections observed on OCT~* Significant tissue prolapse within the stent observed on OCT~* Unprotected left main coronary artery disease~* Target vessel with any lesions with greater than 60% diameter stenosis outside of a range of 5 mm proximal and distal to the target lesion based on visual estimate or on-line quantitative coronary arteriography (QCA).~* Target lesion (or vessel) exhibiting an intraluminal thrombus (occupying \> 50% of the true lumen diameter) at any time.~* Lesion location that is aorto-ostial or within 5 mm of the origin of the left anterior descending (LAD) or left circumflex (LCX).~* Target lesion with side branches \> 2.0mm in diameter.~* Target vessel is excessively tortuous (two bends \> 90˚ to reach the target lesion).~* Target lesion is severely calcified.~* Thrombolysis In Myocardial Infarction (TIMI) flow 0 or 1~* Target lesion is in a bypass graft

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1- COBRA 1 week DAPT (Type: EXPERIMENTAL): COBRA PzF coronary stent followed by dual anti-platelet therapy (DAPT) for one week
- Group 2 - DES 6 month DAPT (Type: ACTIVE_COMPARATOR): Resolute Integrity DES followed by dual anti-platelet therapy (DAPT) for at least 6 months
- Group 3 - COBRA Aspirin (Type: EXPERIMENTAL): COBRA PzF coronary stent followed by aspirin alone

Based on this trial design, predict the completion outcome and termination type (if applicable).